{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:17:58Z","timestamp":1771928278256,"version":"3.50.1"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the efficacy and safety of polyethylene glycol loxenatide (PEG-Loxe) for weight reduction and metabolic improvement in super-obese patients with type 2 diabetes mellitus (T2DM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This was a single-center, single-blind, randomized, controlled clinical trial. A total of 123 study participants were enrolled and randomly assigned to the PEG-Loxe low-dose group (300 \u03bcg\/week), PEG-Loxe high-dose group (400 \u03bcg\/week), and placebo group. In total, 105 participants completed the study. The primary endpoint was the difference in weight reduction between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All three groups had similar baseline characteristics. The least squares mean, 95% confidence interval (LSM, 95% CI) change in weight from baseline to week 24 was greater in the PEG-Loxe 300 \u03bcg group -16.34 (-19.10, -13.58) kg and PEG-Loxe 400 \u03bcg group -21.14 (-23.90, -18.37) kg compared to the placebo group -6.75 (-9.51, -3.99) kg (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001). Glycated hemoglobin levels decreased from the baseline by 0.50%, 1.02%, and 1.34% in the placebo, low-dose, and high-dose groups, respectively. The PEG-Loxe treatment group showed a significant reduction in waist circumference and increased high-density lipoprotein levels during the study period. The rate of adverse drug reactions was higher in the PEG-Loxe 400 \u03bcg group (36.11%) and the PEG-Loxe 300 \u03bcg group (25.00%) than in the placebo group (11.43%). Adverse reactions were predominantly gastrointestinal.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>For super-obese patients with T2DM, continuous treatment with PEG-Loxe for 24 weeks can effectively reduce body weight and achieve good glycemic control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>www.chictr.org.cn<\/jats:ext-link>\n                      , identifier ChiCTR2100052922.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1689040","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:26:03Z","timestamp":1769750763000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of polyethylene glycol loxenatide on weight loss in super-obese patients with type 2 diabetes: a randomized controlled trial"],"prefix":"10.3389","volume":"17","author":[{"given":"Zenglin","family":"Liu","sequence":"first","affiliation":[{"name":"Department of General Surgery, Shandong Provincial Qianfoshan Hospital, Shandong University, Cheeloo College of Medicine","place":["Jinan, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changrong","family":"Song","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital","place":["Jinan, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunlu","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital","place":["Jinan, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhewen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital","place":["Jinan, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanyuan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University","place":["Jinan, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.183","article-title":"The worldwide epidemiology of type 2 diabetes mellitus\u2013present and future perspectives","volume":"8","author":"Chen","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908292","article-title":"Prevalence of diabetes among men and women in China","volume":"362","author":"Yang","year":"2010","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.02.035","article-title":"Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients","volume":"126","author":"Ji","year":"2013","journal-title":"Am J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.17.9.961","article-title":"Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men","volume":"17","author":"Chan","year":"1994","journal-title":"Diabetes Care"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.168118","article-title":"Prevalence and control of diabetes in Chinese adults","volume":"310","author":"Xu","year":"2013","journal-title":"JAMA"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304501","article-title":"Body-mass index and mortality among adults with incident type 2 diabetes","volume":"370","author":"Tobias","year":"2014","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.2014","article-title":"Prevalence and trends in obesity among US adults, 1999-2008","volume":"303","author":"Flegal","year":"2010","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhe.2007.01.006","article-title":"Increases in morbid obesity in the USA: 2000-2005","volume":"121","author":"Sturm","year":"2007","journal-title":"Public Health"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1381\/096089201321209378","article-title":"Obesity-associated disorders before and after weight reduction by vertical banded gastroplasty in morbidly vs super obese individuals","volume":"11","author":"Melissas","year":"2001","journal-title":"Obes Surg"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.316101","article-title":"Obesity phenotypes, diabetes, and cardiovascular diseases","volume":"126","author":"Pich\u00e9","year":"2020","journal-title":"Circ Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"7\u201317","DOI":"10.1016\/0002-9343(84)90429-7","article-title":"Effects of caloric restriction and weight loss on glycemic control, insulin release and resistance, and atherosclerotic risk in obese patients with type II diabetes mellitus","volume":"77","author":"Hughes","year":"1984","journal-title":"Am J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.10.5.639","article-title":"Consensus development conference on diet and exercise in non-insulin-dependent diabetes mellitus","volume":"10","year":"1987","journal-title":"Diabetes Care"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00482-9","article-title":"The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions","volume":"4","author":"Nauck","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14163","article-title":"Efficacy and safety of polyethylene glycol loxenatide as add-on to metformin in patients with type 2 diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 3b trial","volume":"22","author":"Gao","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14198","article-title":"Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: A multicentre, randomized, double-blind, placebo-controlled phase 3a clinical trial","volume":"23","author":"Shuai","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.386","article-title":"Pharmacokinetics and pharmacodynamics of a polyethylene glycol (PEG)-conjugated GLP-receptor agonist once weekly in Chinese patients with type 2 diabetes","volume":"55","author":"Yang","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1106868","article-title":"Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial","volume":"14","author":"Cai","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"529\u201386","DOI":"10.1152\/physrev.00057.2024","article-title":"Proglucagon-derived peptides: human physiology and therapeutic potential","volume":"106","author":"Gasbjerg","year":"2025","journal-title":"Physiol Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103363","article-title":"The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions","volume":"86","author":"Moiz","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1387993","article-title":"Efficacy and safety of polyethylene glycol loxenatide in treating mild-to-moderate diabetic kidney disease in type 2 diabetes patients: a randomized, open-label, clinical trial","volume":"15","author":"Cao","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e70094","DOI":"10.1002\/mco2.70094","article-title":"Once-weekly glucagon-like peptide receptor agonist polyethylene glycol loxenatide protects against major adverse cardiovascular events in patients with type 2 diabetes: a multicenter ambispective cohort study (FLYING trial)","volume":"6","author":"Li","year":"2025","journal-title":"MedComm (2020)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e1659\u2013e1660","DOI":"10.1016\/S2214-109X(25)00275-X","article-title":"Obesity is a disease: global health policy must catch up","volume":"13","author":"Chandiwana","year":"2025","journal-title":"Lancet Glob Health"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12551","article-title":"Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation","volume":"18","author":"Bray","year":"2017","journal-title":"Obes Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1\u201373","DOI":"10.3310\/SKHT8119","article-title":"The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review","author":"Nunns","year":"2025","journal-title":"Health Technol Assess"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-018-3519-y","article-title":"Comparative effectiveness of different bariatric procedures in super morbid obesity","volume":"29","author":"Bettencourt-Silva","year":"2019","journal-title":"Obes Surg"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-021-08979-w","article-title":"The first survey addressing patients with BMI over 50: a survey of 789 bariatric surgeons","volume":"36","author":"Kermansaravi","year":"2022","journal-title":"Surg Endosc"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e204803","DOI":"10.1001\/jamanetworkopen.2020.4803","article-title":"Association of preoperative body weight and weight loss with risk of death after bariatric surgery","volume":"3","author":"Sun","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B31","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1186\/s40001-025-02885-w","article-title":"The earlier metabolic bariatric surgery is performed, the better expected clinical benefit beyond weight loss: a short-term follow-up study","volume":"30","author":"Gao","year":"2025","journal-title":"Eur J Med Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"S3\u2013S14","DOI":"10.1002\/2327-6924.12510","article-title":"Obesity: Risk factors, complications, and strategies for sustainable long-term weight management","volume":"29","author":"Fruh","year":"2017","journal-title":"J Am Assoc Nurse Pract"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0589","article-title":"Effects of liraglutide on weight loss, fat distribution, and \u03b2-cell function in obese subjects with prediabetes or early type 2 diabetes","volume":"40","author":"Santilli","year":"2017","journal-title":"Diabetes Care"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12397","article-title":"Polyethylene glycol loxenatide injections added to metformin effectively improve glycemic control and exhibit favorable safety in type 2 diabetic patients","volume":"9","author":"Chen","year":"2017","journal-title":"J Diabetes"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e3070","DOI":"10.1002\/dmrr.3070","article-title":"Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same","volume":"35","author":"Gentilella","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.250502","article-title":"Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update","volume":"197","author":"Pedersen","year":"2025","journal-title":"CMAJ"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2011.158","article-title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide","volume":"36","author":"Astrup","year":"2012","journal-title":"Int J Obes (Lond)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3\u201314","DOI":"10.1002\/osp4.84","article-title":"Liraglutide for weight management: a critical review of the evidence","volume":"3","author":"Mehta","year":"2017","journal-title":"Obes Sci Pract"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1689040\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:26:30Z","timestamp":1771925190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1689040\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":38,"alternative-id":["10.3389\/fendo.2026.1689040"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1689040","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"article-number":"1689040"}}